<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Early detection of chronic kidney disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Early detection of chronic kidney disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Early detection of chronic kidney disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregorio T Obrador, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marcello Tonelli, MD, SM, FRCPC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 03, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H10268505">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic kidney disease (CKD) is a worldwide public health problem. In the United States, the prevalence of end-stage kidney disease (ESKD) is increasing [
         <a href="#rid1">
          1,2
         </a>
         ]. Patients with ESKD consume a disproportionate share of health care resources [
         <a href="#rid2">
          2-4
         </a>
         ] and experience significant mortality and morbidity and a reduced quality of life [
         <a href="#rid3">
          3,5,6
         </a>
         ].
        </p>
        <p>
         Identifying and managing patients who have early stages of CKD may slow or prevent the progression to ESKD and reduce cardiovascular complications [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         This topic reviews recommendations for population-based CKD screening and case finding, which are collectively termed "early detection." Overviews of the epidemiology and management of CKD and its complications are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7236.html" rel="external">
          "Epidemiology of chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2309893548">
         <span class="h1">
          RATIONALE FOR EARLY DETECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rationale for testing asymptomatic people for CKD is that earlier detection might allow for the implementation of therapeutic interventions and avoidance of inappropriate exposure to nephrotoxic agents, both of which may slow the progression of CKD to end-stage kidney disease (ESKD) [
         <a href="#rid7">
          7,8
         </a>
         ]. The detection of CKD also identifies an important risk factor for cardiovascular disease (CVD). (See
         <a class="medical medical_review" href="/z/d/html/50.html" rel="external">
          "Coronary artery disease and myocardial infarction in young people", section on 'Coronary risk factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">
          "Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Early detection of CKD with reduced glomerular filtration rate (GFR) may also facilitate appropriate dosing of medications and allow timely preparation for kidney replacement, which may improve outcome [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults", section on 'Consequences of late referral'
         </a>
         .)
        </p>
        <p>
         CKD is generally under-recognized, particularly among certain patient subsets [
         <a href="#rid10">
          10-14
         </a>
         ]. In one study of the National Health and Nutrition Examination Survey (NHANES) data from 2003 to 2004, among patients with estimated GFR (eGFR) 45 to 59 mL/minute/1.73 m
         <sup>
          2
         </sup>
         , awareness of kidney disease was reported in only 9.2 percent [
         <a href="#rid14">
          14
         </a>
         ]. Awareness was increased among those with proteinuria, diabetes, or hypertension and among men compared with women.
        </p>
        <p>
         More recent data suggest that awareness of CKD depends on how the question is asked [
         <a href="#rid15">
          15
         </a>
         ]. Asking multiple questions about the possible presence of kidney disease led to a higher apparent prevalence than when only one question was asked [
         <a href="#rid15">
          15
         </a>
         ]. This suggests that earlier studies, which were based on a single question, may have underestimated the true prevalence of awareness. In addition, there is some evidence that the proportion of people with CKD who are aware of their kidney disease is increasing [
         <a href="#rid14">
          14,16
         </a>
         ]. However, awareness of CKD appears lower than awareness of other chronic conditions such as dyslipidemia, hypertension, and diabetes [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H899786122">
         <span class="h1">
          APPROACH TO EARLY DETECTION
         </span>
        </p>
        <p class="headingAnchor" id="H49433465">
         <span class="h2">
          Case finding versus widespread population screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest a case-finding (or targeted) approach to early detection rather than population-based screening. Case finding is a strategy that tests for CKD only in people who are at increased risk. This approach more efficiently identifies individuals who may benefit from intervention and potentially reduces the risk of harms due to false-positive results of testing [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Although population-based screening would almost certainly detect individuals who have no identified risk factors but are at risk for progression to end-stage kidney disease (ESKD) [
         <a href="#rid18">
          18,19
         </a>
         ], a very large number of individuals would need to be tested and treated in order to possibly prevent one case of ESKD [
         <a href="#rid20">
          20-23
         </a>
         ].
        </p>
        <p>
         This was demonstrated in the Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study, in which 40,854 individuals in the Netherlands aged 28 to 75 years were screened for increased urinary albumin excretion [
         <a href="#rid18">
          18
         </a>
         ]. Almost one-half of the individuals who ultimately required kidney replacement therapy had moderately increased albuminuria [
         <a href="#rid18">
          18
         </a>
         ]. Testing only high-risk individuals identified 55 percent of those with moderately increased albuminuria and 87 percent of those who progressed to ESKD. Because 40 to 50 percent of individuals with moderately increased albuminuria did not have risk factors for CKD, the authors advocated screening the general population rather than case finding. However, among 25,597 PREVEND participants who did not have any risk factors for CKD, there were only six cases of ESKD.
        </p>
        <p>
         In addition, although the relatively low cost of testing urine for moderately increased albuminuria favors population-based screening, the total cost of such a program is actually higher since it includes the time and effort to collect specimens, the cost of confirmatory tests for treatment of a positive test, and the costs of monitoring and treatment of complications associated with interventions, as well as any false-positive results.
        </p>
        <p>
         Finally, there is no direct evidence that a therapeutic intervention such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor antagonists decreases the risk of ESKD or a clinically significant loss of glomerular filtration rate (GFR) among individuals who have moderately increased albuminuria but no other risk factors.
        </p>
        <p>
         In a cost-effectiveness analysis performed by the Centers for Disease Control and Prevention (CDC), CKD screening using a test for moderately increased albuminuria was cost effective only for individuals with diabetes or hypertension or aged older than 50 years [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         However, in a subsequent systematic review, case-finding strategies for CKD were cost effective in patients with diabetes and hypertension and probably also in populations with higher incidences of CKD, rapid rates of progression, and more effective drug therapies [
         <a href="#rid23">
          23
         </a>
         ]. Since African Americans are at higher risk for ESKD, case finding in this population may be more cost effective than in the general United States population [
         <a href="#rid25">
          25,26
         </a>
         ]. Similar considerations apply to other specific populations, such as First Nations people in Canada. Despite this, in order to be economically attractive, any early detection strategy would need to improve clinical outcomes compared with the absence of such a strategy, which remains to be conclusively shown [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7236.html" rel="external">
          "Epidemiology of chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         CKD risk scores [
         <a href="#rid28">
          28-30
         </a>
         ] could be helpful to identify people who might benefit from screening for early CKD. Although this approach was cost-effective [
         <a href="#rid31">
          31
         </a>
         ] in one study, further external validation and association with outcomes is needed.
        </p>
        <p>
         The US Preventive Services Task Force (USPSTF) has concluded that evidence is insufficient to assess benefits and screening of asymptomatic adults (excluding testing for and monitoring as part of the management of chronic diseases such as diabetes or hypertension) [
         <a href="#rid32">
          32
         </a>
         ]. The American College of Physicians (ACP) recommends against screening for CKD in asymptomatic adults who do not have risk factors [
         <a href="#rid33">
          33
         </a>
         ], although the American Society of Nephrology (ASN) strongly recommends regular screening for kidney disease, even in the absence of risk factors [
         <a href="#rid34">
          34
         </a>
         ]. This discrepancy between recommendations from generalist and disease-based specialty organizations is also observed for many other conditions.
        </p>
        <p class="headingAnchor" id="H470938791">
         <span class="h2">
          Who should be tested?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adopting a case-finding strategy that restricts testing to people with risk factors for CKD appears to enrich the proportion of positive tests [
         <a href="#rid35">
          35
         </a>
         ]. We believe that patients with risk factors for CKD should be evaluated with a urine test for albuminuria and a blood test for creatinine to estimate GFR. However, the ACP has recommended that patients with or without diabetes who are already taking either an ACE inhibitor or an angiotensin II receptor blocker (ARB) should not be tested for proteinuria [
         <a href="#rid33">
          33
         </a>
         ], although this recommendation is controversial [
         <a href="#rid36">
          36
         </a>
         ]. Patients who are at risk for glomerulonephritis should be screened for hematuria with a urinalysis. (See
         <a class="local">
          'Methods of testing for CKD'
         </a>
         below.)
        </p>
        <p>
         We recommend that all individuals be assessed for CKD risk as part of routine health examinations [
         <a href="#rid1">
          1,37
         </a>
         ]. This is consistent with recommendations of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines for CKD, which have been reviewed and endorsed by the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease [
         <a href="#rid38">
          38
         </a>
         ] and the KDIGO 2019 Controversies Conference on early identification and intervention of CKD [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The presence of the following risk factors should trigger formal testing for CKD in adults [
         <a href="#rid40">
          40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of diabetes, hypertension, cardiovascular disease, HIV or hepatitis C virus infection, malignancy, autoimmune diseases, nephrolithiasis, or recurrent urinary tract infections (UTIs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Origin from a specific population, such as First Nations people of Canada [
         <a href="#rid41">
          41-44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of kidney disease [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sickle cell trait (SCT) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Formal testing for CKD may also be performed in people with multiple cardiovascular risk factors but without known CVD, although the number of risk factors that should prompt such testing is unknown (see
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"
         </a>
         ). Evaluation for CKD may be of benefit among adults living in areas where CKD incidence is unusually high ("CKD hotspots"), such as certain regions of Central America, Sri Lanka, and the Balkans [
         <a href="#rid46">
          46-49
         </a>
         ]. However, this will require further study before making geographically based recommendations for CKD testing [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Although some have proposed testing for CKD in all patients aged more than 60 years [
         <a href="#rid37">
          37
         </a>
         ], this approach is not based on available evidence, and more data are needed before such screening is recommended. If an early detection approach is desired, the initiation, frequency, and discontinuation of testing for CKD should be individualized based on kidney and cardiovascular risk profiles and individual preferences, rather than at a specific chronological age. Moreover, in the setting of limited life expectancy, if CKD is detected, any change in treatment should carefully weigh the risks and benefits [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94901.html" rel="external">
          "Kidney palliative care: Conservative kidney management"
         </a>
         .)
        </p>
        <p>
         Race/ethnicity, poor access to health care or low socioeconomic status, high-risk occupations, environmental exposures, genetic risk factors, prior acute kidney injury, and preeclampsia may also appropriately trigger testing for CKD [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4189002647">
         <span class="h3">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following risk factors should be considered when determining whether to test an asymptomatic patient for kidney disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes, hypertension, and CVD
         </strong>
         – A history of diabetes, hypertension, or CVD confers the highest risk for developing CKD, and individuals who have such a history should be evaluated for CKD [
         <a href="#rid37">
          37
         </a>
         ]. The CKD risk is discussed in individual topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Secondary or contributing causes of hypertension'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">
          "Chronic kidney disease and coronary heart disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Origin from specific populations
         </strong>
         – First Nations people of Canada, Native Americans, and Aboriginal Australians are at increased risk of CKD and kidney failure and may have reduced access to health services that in turn decrease the likelihood of opportunistic detection of previously unrecognized CKD [
         <a href="#rid41">
          41-44
         </a>
         ]. This increases the theoretical appeal of case finding in this population, although whether such a strategy will lead to clinical benefit is as yet unproven.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sickle cell trait (SCT)
         </strong>
         – Observational studies demonstrate that adults with SCT have a significantly higher risk of CKD than those without SCT and that the magnitude of the excess risk appears clinically relevant. In one pooled analysis, the absolute risk of incident CKD was 8.5 percent higher over long-term follow-up among those with SCT as compared with those without (95% CI 5.1-12.3%) [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">
          "Sickle cell disease effects on the kidney"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other chronic illnesses including HIV, hepatitis C, or other chronic viral infections
         </strong>
         – Both chronic viral infection and retroviral treatment are associated with CKD. (See
         <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">
          "Overview of kidney disease in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">
          "HIV-associated nephropathy (HIVAN)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">
          "Overview of kidney disease associated with hepatitis C virus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Current or history of malignancy
         </strong>
         –
         <strong>
         </strong>
         Cancer or cancer treatment can cause acute kidney injury and CKD. (See
         <a class="medical medical_review" href="/z/d/html/7173.html" rel="external">
          "Overview of kidney disease in patients with cancer", section on 'Causes of CKD in patients with cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nephrotoxic medication
         </strong>
         – Chronic use of nephrotoxic medications, such as nonsteroidal anti-inflammatory agents,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and possibly proton pump inhibitors, confers a higher risk of CKD. (See
         <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">
          "NSAIDs: Acute kidney injury", section on 'Risk of chronic kidney disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Kidney disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obesity
         </strong>
         – Observational studies have suggested that obesity may also be associated with CKD [
         <a href="#rid51">
          51-58
         </a>
         ]. However, we generally do not routinely evaluate patients with obesity for CKD unless other indications are present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History of kidney disease during childhood
         </strong>
         – A nationwide population-based cohort study including 1,521,501 Israeli adolescents demonstrated an increased risk of ESKD (defined as starting dialysis or receiving a kidney transplant) among individuals with a history of childhood kidney disease [
         <a href="#rid59">
          59
         </a>
         ]. Adolescents (mean age 17.7 years) were screened before compulsory military service between the years 1967 to 1997, and data were linked to the Israeli ESKD registry. Individuals were excluded from analysis if they had abnormal kidney function, hypertension, diabetes, systemic lupus erythematosus, vasculitis, any rheumatologic disease, or cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A history of any kidney disease (including congenital anomalies of the kidney and urinary tract, pyelonephritis, and glomerular disease) was associated with increased risk of ESKD (hazard ratio 4.19, 95% CI 3.52-4.99). The magnitude of risk was independent of the type of kidney disease. Individuals with a history of childhood kidney disease also presented with ESKD at a younger age (42 years versus 49 years in individuals without such a history).
        </p>
        <p>
        </p>
        <p>
         Specific details regarding the individual kidney diseases (such as age of initial presentation and medications and/or surgical interventions used during treatment) are lacking, which limits the interpretation of this observational study [
         <a href="#rid60">
          60
         </a>
         ]. In addition, the study did not report imaging data, and it is possible that individuals with abnormal kidney imaging were included in the analysis; such individuals are considered by current criteria to have CKD, even in the absence of reduced kidney function (see
         <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">
          "Definition and staging of chronic kidney disease in adults", section on 'Definition of CKD'
         </a>
         ). In addition, the absolute incidence of ESKD among adults with a history of kidney disease in childhood was very low (16.3 to 28.3 cases per 100,000 person-years).
        </p>
        <p class="headingAnchor" id="H2666200">
         <span class="h2">
          Methods of testing for CKD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are selected for CKD evaluation should have a urine test for albumin and a blood test for creatinine to estimate GFR. The preferred testing strategy for albuminuria is measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample. (See
         <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">
          "Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults", section on 'Quantitative measurement'
         </a>
         .)
        </p>
        <p>
         Urinary albumin is more strongly associated with clinical outcomes than total urinary protein, and it is required to classify CKD according to KDIGO criteria [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Evaluating for hematuria with a urinalysis should be done in selected populations that are at increased risk for glomerulonephritis [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p>
         The estimated GFR (eGFR) and the threshold of &lt;60 mL/min/1.73 m
         <sup>
          2
         </sup>
         that defines CKD may have limitations, particularly among older adults (see
         <a class="medical medical_review" href="/z/d/html/89217.html" rel="external">
          "The aging kidney"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">
          "Assessment of kidney function"
         </a>
         ). Some have advocated for using serum creatinine and cystatin C measurements together for initial CKD diagnosis and staging. This diagnostic approach improves accuracy in people with true eGFR between 45 and 59 mL/min/1.73 m
         <sup>
          2
         </sup>
         . People with CKD as identified by both serum creatinine and cystatin C have a higher risk of cardiovascular events, kidney failure, and death than those with CKD identified by serum creatinine alone. However, the advantages of combination testing are substantially attenuated at lower true eGFR. Thus, it might be preferable to use a lower GFR threshold for early detection strategies, such as &lt;45 mL/min/1.73 m
         <sup>
          2
         </sup>
         , since the combination testing strategy adds complexity and cost that may be particularly challenging for resource-limited countries [
         <a href="#rid38">
          38,39
         </a>
         ]. Additional studies are needed to determine the optimal testing strategy for early detection of CKD.
        </p>
        <p>
         Depending on the presence of particular risk factors, additional testing may be required. As an example, an individual with a family history of polycystic kidney disease may require an ultrasound.
        </p>
        <p>
         Once the diagnosis of CKD is established, the cause and/or potentially reversible factors should be identified and treated. (See
         <a class="medical medical_review" href="/z/d/html/102837.html" rel="external">
          "Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults"
         </a>
         .)
        </p>
        <p>
         In addition, CKD should be staged according to the KDIGO revised classification  (
         <a class="graphic graphic_table graphicRef70597" href="/z/d/graphic/70597.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults", section on 'Definition and classification'
         </a>
         .)
        </p>
        <p>
         This classification is based on laboratory evaluation of the severity of kidney disease, association of level of kidney function with complications, and stratification of risks for loss of kidney function and development of CVD.
        </p>
        <p class="headingAnchor" id="H946508198">
         <span class="h2">
          Frequency of testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of testing for CKD in high-risk groups has not been rigorously studied, and recommendations are opinion based. The National Kidney Disease Education Program (NKDEP) of the National Institutes of Health (NIH) and the UK's National Institute for Health Research recommend yearly testing among patients with diabetes [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">
          "Overview of general medical care in nonpregnant adults with diabetes mellitus", section on 'Monitoring for increased urinary albumin excretion'
         </a>
         .)
        </p>
        <p>
         Patients with hypertension should be tested at diagnosis, upon initiation of therapy, and every three years thereafter. Individuals with a family history of CKD should be tested every three years. Individuals with other risk factors may be tested less frequently [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         The KDIGO Controversies Conference concluded that the frequency of repeat testing could be based on each individual's risk of developing CKD. Risk equations that estimate five-year CKD probabilities could be used to guide the timing of subsequent testing [
         <a href="#rid30">
          30,39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2374564367">
         <span class="h1">
          EARLY DETECTION PROGRAMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The National Kidney Foundation (NKF)-sponsored Kidney Early Evaluation Program (KEEP) was a screening program targeted at individuals 18 years or older at high risk for developing CKD because they have diabetes, hypertension, and/or first-order relatives with those conditions or kidney disease. KEEP offered free blood and urine testing, on-site consultation by a clinician, referrals, and additional follow-up for those whose test results were outside normal ranges [
         <a href="#rid63">
          63,64
         </a>
         ]. Data collected included age, family history, height, weight, blood pressure, the presence of moderately increased albuminuria, pyuria, hematuria, plasma glucose, and serum creatinine concentration [
         <a href="#rid65">
          65
         </a>
         ]. Among 89,622 KEEP participants, the overall CKD prevalence was 26 percent, of which 17 percent had stage 3 and 1 percent stage 4 or 5 [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has also launched the National Kidney Disease Education Program (NKDEP) [
         <a href="#rid67">
          67
         </a>
         ]. This program is designed to increase awareness of the risk for CKD, especially among providers for high-risk groups, and to develop straightforward management steps for primary care clinicians based upon the formal guidelines being developed by the Kidney Disease Outcomes Quality Initiative (KDOQI) [
         <a href="#rid67">
          67
         </a>
         ]. Similar strategies have been undertaken globally, including adaptations of the KEEP program in Japan and Mexico, the SeeCKD program in Canada, and the Kidney Evaluation for You program in Australia [
         <a href="#rid35">
          35,68-70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3677749855">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">
          "Society guideline links: Chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10269534">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Identifying and managing patients who have early stages of chronic kidney disease (CKD) may slow or prevent the progression to end-stage kidney disease (ESKD) and reduce cardiovascular complications. Early detection of CKD might also facilitate appropriate dosing of medications and allow timely preparation for kidney replacement, which may improve outcome. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Rationale for early detection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest evaluating high-risk individuals for CKD, which is termed "case-finding" (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Important risk factors for CKD include diabetes, hypertension, and cardiovascular disease (CVD); other risk factors to be considered include a positive family history for kidney disease, human immunodeficiency virus (HIV) or hepatitis C virus infection, sickle cell trait (SCT), malignancy, autoimmune diseases, nephrolithiasis, and recurrent urinary tract infections (UTIs). (See
         <a class="local">
          'Approach to early detection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are selected for CKD evaluation should have a urine test for albumin in a random urine sample and a blood test for creatinine to estimate glomerular filtration rate (GFR). Additional testing, such as kidney ultrasonography, may be required in selected individuals (eg, in patients with a family history of polycystic kidney disease). (See
         <a class="local">
          'Methods of testing for CKD'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The frequency of testing for CKD in high-risk groups has not been rigorously studied, and recommendations are opinion based. We suggest that patients with diabetes are tested on a yearly basis and patients with hypertension at diagnosis, upon initiation of therapy, and every three years thereafter. Individuals with a family history of CKD should be tested every three years. Risk equations that estimate five-year CKD probabilities could also guide the timing of subsequent testing. (See
         <a class="local">
          'Frequency of testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H421308255">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Brian JG Pereira, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.
          </a>
         </li>
         <li class="breakAll">
          2016 USRDS Annual Data Report. https://www.usrds.org/adr.aspx (Accessed on December 01, 2016).
         </li>
         <li class="breakAll">
          United States Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2009.
         </li>
         <li class="breakAll">
          United States Renal Data System. USRDS 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2000.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McClellan WM, Anson C, Birkeli K, Tuttle E. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol 1991; 44:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 1997; 30:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira BJ. Optimization of pre-ESRD care: the key to improved dialysis outcomes. Kidney Int 2000; 57:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remuzzi G, Benigni A, Finkelstein FO, et al. Kidney failure: aims for the next 10 years and barriers to success. Lancet 2013; 382:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nickolas TL, Frisch GD, Opotowsky AR, et al. Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 2004; 44:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis 1997; 29:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan TP, Sloand JA, Winters PC, et al. Chronic kidney disease prevalence and rate of diagnosis. Am J Med 2007; 120:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plantinga LC, Boulware LE, Coresh J, et al. Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med 2008; 168:2268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuot DS, Zhu Y, Velasquez A, et al. Variation in Patients' Awareness of CKD according to How They Are Asked. Clin J Am Soc Nephrol 2016; 11:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One 2014; 9:e110535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-García G, Gutiérrez-Padilla AJ, Chávez-Iñiguez J, et al. Identifying undetected cases of chronic kidney disease in Mexico. Targeting high-risk populations. Arch Med Res 2013; 44:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Velde M, Halbesma N, de Charro FT, et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 2009; 20:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imai E, Yamagata K, Iseki K, et al. Kidney disease screening program in Japan: history, outcome, and perspectives. Clin J Am Soc Nephrol 2007; 2:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fried L. Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol 2009; 20:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol 2006; 17:2120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gansevoort RT, Bakker SJ, de Jong PE. Early detection of progressive chronic kidney disease: is it feasible? J Am Soc Nephrol 2006; 17:1218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komenda P, Ferguson TW, Macdonald K, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis 2014; 63:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 2010; 55:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoerger TJ, Wittenborn JS, Zhuo X, et al. Cost-effectiveness of screening for microalbuminuria among African Americans. J Am Soc Nephrol 2012; 23:2035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vargas RB, Norris KC. Kidney disease progression and screening cost-effectiveness among African Americans. J Am Soc Nephrol 2012; 23:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuot DS, Peralta CA. To screen or not to screen: that is not (yet) the question. Clin J Am Soc Nephrol 2015; 10:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bang H, Vupputuri S, Shoham DA, et al. SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med 2007; 167:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kshirsagar AV, Bang H, Bomback AS, et al. A simple algorithm to predict incident kidney disease. Arch Intern Med 2008; 168:2466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson RG, Grams ME, Ballew SH, et al. Development of Risk Prediction Equations for Incident Chronic Kidney Disease. JAMA 2019; 322:2104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yarnoff BO, Hoerger TJ, Simpson SK, et al. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol 2017; 18:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moyer VA, U.S. Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaseem A, Hopkins RH Jr, Sweet DE, et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2013; 159:835.
          </a>
         </li>
         <li class="breakAll">
          http://www.asn-online.org/news/2013/ASN_COMM_ACP_Screening_Response_102213_R12.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galbraith LE, Ronksley PE, Barnieh LJ, et al. The See Kidney Disease Targeted Screening Program for CKD. Clin J Am Soc Nephrol 2016; 11:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molitoris BA. Screening: Screening for kidney disease--a lost opportunity. Nat Rev Nephrol 2014; 10:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2021; 99:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naik RP, Derebail VK, Grams ME, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 2014; 312:2115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritte R, Luke J, Nelson C, et al. Clinical outcomes associated with albuminuria in central Australia: a cohort study. BMC Nephrol 2016; 17:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoy WE. Kidney disease in Aboriginal Australians: a perspective from the Northern Territory. Clin Kidney J 2014; 7:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeates K, Tonelli M. Chronic kidney disease among Aboriginal people living in Canada. Clin Nephrol 2010; 74 Suppl 1:S57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavallee B, Chartrand C, McLeod L, et al. Mass screening for chronic kidney disease in rural and remote Canadian first nations people: methodology and demographic characteristics. Can J Kidney Health Dis 2015; 2:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li PK, Ng JK, Cheng YL, et al. Relatives in silent kidney disease screening (RISKS) study: A Chinese cohort study. Nephrology (Carlton) 2017; 22 Suppl 4:35.
          </a>
         </li>
         <li class="breakAll">
          Wesseling C, Crowe J, Hogstedt C, et al. Mesoamerican Nephropathy: Report from the First International Research Workshop on MeN. Central American Institute for Studies on Toxic Substances (IRET-UNA), Program on Work, Environment and Health in Central American (SALTRA), San Jose, PR 2013. p. 239.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín-Cleary C, Ortiz A. CKD hotspots around the world: where, why and what the lessons are. A CKJ review series. Clin Kidney J 2014; 7:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayatilake N, Mendis S, Maheepala P, et al. Chronic kidney disease of uncertain aetiology: prevalence and causative factors in a developing country. BMC Nephrol 2013; 14:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bui-Klimke T, Wu F. Evaluating weight of evidence in the mystery of Balkan endemic nephropathy. Risk Anal 2014; 34:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obrador GT, Schultheiss UT, Kretzler M, et al. Genetic and environmental risk factors for chronic kidney disease. Kidney Int Suppl 2017; 7:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferris M, Hogan SL, Chin H, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol 2007; 2:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elsayed EF, Sarnak MJ, Tighiouart H, et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis 2008; 52:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang Y, Ryu S, Choi Y, et al. Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study. Ann Intern Med 2016; 164:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryu S, Chang Y, Woo HY, et al. Changes in body weight predict CKD in healthy men. J Am Soc Nephrol 2008; 19:1798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AR, Chen Y, Still C, et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int 2016; 90:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vivante A, Golan E, Tzur D, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med 2012; 172:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calderon-Margalit R, Golan E, Twig G, et al. History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease. N Engl J Med 2018; 378:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingelfinger JR. A Disturbing Legacy of Childhood Kidney Disease. N Engl J Med 2018; 378:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farmer AJ, Stevens R, Hirst J, et al. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness. Health Technol Assess 2014; 18:1.
          </a>
         </li>
         <li class="breakAll">
          National Kidney Disease Education Program (NKDEP) http://www.nkdep.nih.gov/professionals/chronic_kidney_disease.htm#diagnosis. (Accessed on October 09, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annual Data Report of the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2003; 42 (Suppl 4):S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2003; 42:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Kidney Foundation Kidney Early Evaluation Program (KEEP), KEEP 2006 data report. Am J Kidney Dis 2007; 49 (Suppl 3):S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Kidney Foundation. Kidney Early Evaluation Program. Annual Data Report. Am J Kidney Dis 2009; 53 (Suppl 4):S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narva A. Screening is part of kidney disease education. Clin J Am Soc Nephrol 2007; 2:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi S, Okada K, Yanai M. The Kidney Early Evaluation Program (KEEP) of Japan: results from the initial screening period. Kidney Int Suppl 2010; :S17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obrador GT, García-García G, Villa AR, et al. Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) México and comparison with KEEP US. Kidney Int Suppl 2010; :S2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew TH, Corso O, Ludlow M, et al. Screening for chronic kidney disease in Australia: a pilot study in the community and workplace. Kidney Int Suppl 2010; :S9.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15768 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1986062" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9261030" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9273824" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10620220" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Optimization of pre-ESRD care: the key to improved dialysis outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23727164" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Kidney failure: aims for the next 10 years and barriers to success.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15264176" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15563563" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9041212" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17976426" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Chronic kidney disease prevalence and rate of diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001205" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Patient awareness of chronic kidney disease: trends and predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27340288" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Variation in Patients' Awareness of CKD according to How They Are Asked.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25427285" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24211755" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Identifying undetected cases of chronic kidney disease in Mexico. Targeting high-risk populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19211710" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Screening for albuminuria identifies individuals at increased renal risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942780" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Kidney disease screening program in Japan: history, outcome, and perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19279125" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Are we ready to screen the general population for microalbuminuria?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16825331" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Screening, monitoring, and treatment of albuminuria: Public health perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16611711" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Early detection of progressive chronic kidney disease: is it feasible?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24529536" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cost-effectiveness of primary screening for CKD: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20116910" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23204444" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cost-effectiveness of screening for microalbuminuria among African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23160510" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Kidney disease progression and screening cost-effectiveness among African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25779993" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : To screen or not to screen: that is not (yet) the question.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325299" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19064831" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A simple algorithm to predict incident kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31703124" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Development of Risk Prediction Equations for Incident Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28288579" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22928170" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24145991" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24145991" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27197905" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The See Kidney Disease Targeted Screening Program for CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24296624" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Screening: Screening for kidney disease--a lost opportunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17568785" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33127436" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25393378" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27495237" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical outcomes associated with albuminuria in central Australia: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25503952" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Kidney disease in Aboriginal Australians: a perspective from the Northern Territory.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20979965" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Chronic kidney disease among Aboriginal people living in Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27408755" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Mass screening for chronic kidney disease in rural and remote Canadian first nations people: methodology and demographic characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29155503" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Relatives in silent kidney disease screening (RISKS) study: A Chinese cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29155503" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Relatives in silent kidney disease screening (RISKS) study: A Chinese cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25859368" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : CKD hotspots around the world: where, why and what the lessons are. A CKJ review series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23981540" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Chronic kidney disease of uncertain aetiology: prevalence and causative factors in a developing country.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24954501" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Evaluating weight of evidence in the mystery of Balkan endemic nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Genetic and environmental risk factors for chronic kidney disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942783" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18511168" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Waist-to-hip ratio, body mass index, and subsequent kidney disease and death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18440684" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26857595" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18495960" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Changes in body weight predict CKD in healthy men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27181999" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Bariatric surgery is associated with improvement in kidney outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23108588" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Body mass index in 1.2 million adolescents and risk for end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16389251" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Body mass index and risk for end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29385364" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29385363" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A Disturbing Legacy of Childhood Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24576414" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24576414" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Annual Data Report of the Kidney Early Evaluation Program (KEEP)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12830453" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : National Kidney Foundation Kidney Early Evaluation Program (KEEP), KEEP 2006 data report
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Annual Data Report
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17928467" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Screening is part of kidney disease education.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20186175" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The Kidney Early Evaluation Program (KEEP) of Japan: results from the initial screening period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20186176" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) México and comparison with KEEP US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20186177" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Screening for chronic kidney disease in Australia: a pilot study in the community and workplace.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
